03933.HK
The United Laboratories International Holdings Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 8.36
−0.65%Year over year
Reported trailing growth
- Revenue
- -4.4%
- EBITDA
- -27.9%
- EBIT
- -36.9%
- EPS
- -30.8%
- Free cash flow
- -72.8%
- Operating cash flow
- -33.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.2%
- EBITDA
- +3.7%
- EBIT
- +4.1%
- Net income
- +9.7%
- EPS
- +8.5%
- Free cash flow
- -11.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026